ArriVent BioPharma EBIT

ArriVent BioPharma (AVBP) currently reports a EBIT of $-110M as of March 2026. That compares with $-74M in the prior-year period — down 52.8% year over year. That is below the sector sector average of $-63M. Use the charts on this page to explore ArriVent BioPharma's EBIT history and peer comparisons.

ArriVent BioPharma's EBIT decreased from $-74M to $-110M — a 52.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ArriVent BioPharma's EBIT of $-110M is lower than the its sector sector average of $-63M. That is roughly 79.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

ArriVent BioPharma reported $-110M in EBIT as of March 2026. That compares with $-74M in the prior-year period — down 52.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-110M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-63M. From there, open related valuation or income-statement pages for ArriVent BioPharma, and consider following AVBP for alerts when major investors trade the stock.